Comparison of Once-Biweekly Administration of Epoetin-α with Darbepoetin-α in Chronic Kidney Disease Patients Not Receiving Dialysis
Year: 2010
Type: article
Study design: Clinical Trial
Abstract: Purpose: It is very important to correct renal anemia by erythropoiesis stimulating agents (ESA) be-cause anemia is associated with poor outcomes in chronic kidney disease (CKD) patients. We investigated whether once-biweekly (Q2W) treatment with epoetin- (EPO-) is as effective as Q2W darbe-poetin- (DA-α) in CKD patients who are not on dialysis. Methods: Fifteen CKD patients not receiving dialysis with renal anemia (M:F 6:9, age 60.1±7.2 years, eGFR-MDRD 15.7±6.4 mL/min/1.73m2, DM 46.7%) were enrolled. All patients received Q2W subcutaneous DA-α(40μg) for 10 weeks. After 6 weeks of wash-out period, patients were switched to Q2W subcutaneous EPO- (10,000 IU) for 10 weeks. Results: There were no significant differences in baseline parameters, such as hemoglobin (Hb), serum ferritin, and transferrin saturation, between before DA- therapy and before EPO-α therapy. Hb levels significantly increased after completion of ESA therapy (DA-α, 9.8±0.4 vs. 10.4±0.6 g/dL, p=0.001; EPO-α, 9.6±0.7 vs. 10.2±0.4 g/dL, p=0.003). After completion of ESA therapy, Hb levels did not reveal significant differences between two groups (p=0.123). Erythropoietin resistance index (8.2±1.6 vs. 8.4±1.5 IU/kg weight/g hemoglobin/week, p=0.136) and % increase of Hb (106.7±5.5 vs. 106.8±6.4%, p= 0.776) were not significantly different between DA-α therapy and EPO-α therapy. There were no signi-ficant adverse effects observed during study periods. Conclusion: These findings indicate that Q2W high dose (10,000 IU) of EPO-α therapy in CKD patients who are not on dialysis may be effective in maintaining Hb levels as Q2W DA-α therapy.
Institution: Konkuk University
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W2396479969